Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Uterine Cancer
Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Patients With Uterine Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Time to treatment (time from disease diagnosis to initiation of treatment) impacts outcomes in uterine cancer. When controlled for stage, patients with longer time to treatment tend to have less favorable outcomes. Similarly, longer time to treatment has a negative impact on patients' quality of life and markers for anxiety. Our experience at this institution suggests that the time to referral (time from uterine cancer diagnosis and the patients' first encounter with the oncologist) is variable and presents the greatest opportunity for decreasing time to treatment. Among the factors that contribute to the time to referral are the time taken by the referring provider to relay the diagnosis to the patient, time taken to schedule an appointment with the specialist, and the patient's availability to keep an appointment.
Virtual visits provide an opportunity to expedite consultation with the treating oncologist by removing some of the barriers that delay face-to-face visits. Among these barriers are patients' availability for a short notice face-to-face visit based on their work or family obligations, access to transportation, and mental preparedness.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Uterine cancer diagnosis on biopsy read by Cleveland Clinic Pathology Department
- Patients must be willing to participate in a virtual visit as the initial meeting with an oncologist at the Cleveland Clinic.
- Receive care at Fairview Hospital, Hillcrest Hospital or Cleveland Clinic Main Campus
- Internet connected smartphone or internet connected computer with webcam
- Participants must have email access
- English speaking
- Competent to make clinic decisions
Exclusion Criteria:
- No diagnosis of uterine cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Rapid first contact virtual visit
Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed.
Subjects will be randomized after accepting offer of a virtual visit.
|
Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
|
|
PLACEBO_COMPARATOR: First contact in person office visit
Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed.
Subjects will be randomized after accepting offer of a virtual visit.
|
Scheduled office visit with oncologist following uterine cancer diagnosis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to treatment following diagnosis to treatment initiation
Time Frame: 30 days
|
How long between diagnosis to treatment
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of anxiety demonstrated when virtual visits are added
Time Frame: 30 days
|
Level of anxiety using GAD-7
|
30 days
|
|
Number of patients willing to pay for a virtual visit
Time Frame: 30 days
|
Assess patients valuation of virtual visits by measuring their willingness to pay
|
30 days
|
|
Number of patients with improved satisfaction scores
Time Frame: 30 days
|
Determine whether the addition of a rapid virtual visit improves patients satisfaction
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jason Knight, MD, Cleveland Clinic, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE3818
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.